ELYM - Eliem to discontinue development of lead asset as mid-stage pain trial fails

• Clinical-stage biotech Eliem Therapeutics ( NASDAQ: ELYM ) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP).
• The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS).
• The results indicated that ETX-810 did not achieve a statistically significant separation from placebo in the primary endpoint.
• The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.

For further details see: